We are shengda pharmaceutical co., ltd, we product offer bortezomib & intermediates
Bortezomib-pinanediol 205393-22-2 more than 98%
Bortezomib 179324-69-7 more than 99%
(s)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino] propanoic acid 114457-94-2 (ar, 3as, 4s, 6s, 7ar)-hexahydro-3a, 8, 8-trimethyl-alpha-(2-methylpropyl)-4, 6-methano-1, 3, 2-benzodioxaborole-2-methanamine 2, 2, 2-trifluoroacetate 179324-87-9
We are shengda pharmaceutical co., ltd, we product offer bortezomib & intermediates
Bortezomib-pinanediol 205393-22-2 more than 98%
Bortezomib 179324-69-7 more than 99%
(s)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino] propanoic acid 114457-94-2 (ar, 3as, 4s, 6s, 7ar)-hexahydro-3a, 8, 8-trimethyl-alpha-(2-methylpropyl)-4, 6-methano-1, 3, 2-benzodioxaborole-2-methanamine 2, 2, 2-trifluoroacetate 179324-87-9
Bortezomib(CAS:179324-69-7)
Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified. WHITE POWDER. HPLC.spectrum of MS.and NMR would be supplied
Name Fondaparinux sodium Molecular Structure Molecular Formula C31H43N3Na10O49S8 Molecular Weight 1728.08 CAS Registry Number 114870-03-0.
Supplier: Bortezomib, geftinib, ivabradine hydrochloride, raltegravir potassium salt, sitagliptin phosphate monohydrate, azelnidipine, rasagiline mesylate, paliperidone, cefbuperazone, butoconazole nitrate, proparacaine hydrochloride, naloxone hydrochloride dihydrate, cefcapene pivoxil hydrochloride, dapoxetine hydrochloride, chemical intermediates, dapoxetine hydrochloride, vecuronium bromide, naloxone hydrochloride, landiolol hydrochloride, silodosin
Buyer: Bortezomib, geftinib, ivabradine hydrochloride, raltegravir potassium salt, sitagliptin phosphate monohydrate, azelnidipine, rasagiline mesylate, paliperidone, cefbuperazone, butoconazole nitrate, proparacaine hydrochloride, naloxone hydrochloride dihydrate, cefcapene pivoxil hydrochloride, dapoxetine hydrochloride, chemical intermediates, dapoxetine hydrochloride, vecuronium bromide, naloxone hydrochloride, landiolol hydrochloride, silodosin
Supplier: Paclitaxel, docetaxel, oxaliplatin, bortezomib, doxorubicin hydrochloride, entecavir monohydrate, tenofovir disoproxil fumarate emtricitabine, valsartan, tolvaptan, lcz696, candesartan cilexetil, apixaban, ezetimibe, rivaroxaban, clopidogrel, rosuvastatin calcium, pitavastatin calcium, glipizide, canagliflozin, linagliptin, finafloxacin hydrochloride, gamithromycin, micafungin sodium, reboxetine mesylate, vonoprazan fumarate, roflumilast, topiroxostat
